SCHEMBL24620566

SCHEMBL24620566

Cc1cc(CNC(=O)c2ccn(S(=O)(=O)c3ccccc3)n2)on1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.44
▸ AKR1C3 P42330 1/20 0.42
▸ AKR1C1 Q04828 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ GRM5 P41594 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ LIPC P11150 1/20 0.40
▸ LIPG Q9Y5X9 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ KLKB1 P03952 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22588738 0.92 NPC1 (0.41) TDP1AKR1C3AKR1C1POLBSMN1; SMN2
SCHEMBL22588752 0.91 NPC1 (0.41) TDP1AKR1C3AKR1C1POLBSMN1; SMN2
SCHEMBL29808253 0.91 NPC1 (0.41) TDP1AKR1C3AKR1C1POLBSMN1; SMN2
SCHEMBL24620637 0.90 THRB (0.45) TDP1POLBSMN1; SMN2USP2NPC1
SCHEMBL22588832 0.88 RAB9A (0.47) TDP1CYP1A2POLBSMN1; SMN2NPC1
SCHEMBL22588736 0.88 TDP1 (0.41) TDP1CYP1A2CYP2D6CYP2C19POLB
SCHEMBL29808123 0.88 TDP1 (0.41) TDP1CYP1A2CYP2D6CYP2C19POLB
SCHEMBL21875138 0.80 KLKB1 (0.53) POLBUSP2NPC1RAB9AKMT2A
SCHEMBL24620714 0.76 GRM4 (0.39) TDP1AKR1C3AKR1C1POLBSMN1; SMN2
SCHEMBL6403162 0.74 POLB (0.54) CYP1A2CYP2D6CYP2C19POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220095-A1 N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H LUNDBECK AS (DK) 2022-07-14 — — US claimed
CN-113692405-A Derivatives of N- ((heteroaryl) methyl) -1-tosyl-1H-pyrazole-3-carboxamide as KV3 potassium channel activators for the treatment of neurological or psychiatric disorders H.隆德贝克有限公司 2021-11-23 — — CN claimed
US-20220220095-A1 N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H LUNDBECK AS (DK) 2022-07-14 — — US disclosed
US-20220220095-A1 N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H LUNDBECK AS (DK) 2022-07-14 — — US disclosed
CN-113692405-A Derivatives of N- ((heteroaryl) methyl) -1-tosyl-1H-pyrazole-3-carboxamide as KV3 potassium channel activators for the treatment of neurological or psychiatric disorders H.隆德贝克有限公司 2021-11-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220095-A1 N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS KCNA3, KCNK3, KCND3 TDP1 1260/4885AKR1C3 2721/4885AKR1C1 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback